Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102. Kasi PM, Grothey A. Ann Oncol 2020;31:15-16.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kasi PM, Grothey A. Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102. Ann Oncol 2020;31:15-16.
PMID: 31912790